Media.Player

"YLN for Cardiac Indication"

Detailed Technology Description

Synthetic vaccine and Immunogenic Fusion Proteins for pneumococcal infections (SJ-05-0036, SJ-10-0028, SJ-13-0032).A vaccine comprising synthetically linked domains of choline binding protein A (C

*Abstract

Synthetic vaccine and Immunogenic Fusion Proteins for pneumococcal infections (SJ-05-0036, SJ-10-0028, SJ-13-0032).A vaccine comprising synthetically linked domains of choline binding protein A (CbpA) from Streptococcus pneumonia, and a new type of pneumococcus vaccine component in which a T-cell epitope (e.g. Pneulmolysin toxoid) is fused to immunogenic fragments of choline binding protein A (CbpA). This new fused vaccine component provides an easier, less costly and more efficient way to elicit an immune response to both the T-cell epitope and CbpA as compared to a mixture of separate antigens. The CbpA fragment used preferably comprises synthetically linked domains of CbpA. The CbpA peptide-pneumolysoid fusion construct is a viable broadly protective pneumococcal vaccine that potentially adds protection against other meningeal pathogens; and may be useful for treating or preventing infections such as sepsis, meningitis, and pneumonia. Also, SJ-13-0032, "YLN for Cardiac Indication," involves using these vaccine components to avoid adverse cardiac events caused by pneumonia infections (This is co-owned with Univ. of Texas Health Science Center.)Granted Patents or Published ApplicationsCbpA fragment (SJ-05-0036) issued May 13, 2014 as U.S. Patent No. 8,722,055; additional U.S. Appln. pending. CbpA peptide-pneumolysoid fusion construct (SJ-10-0028) pending in the U.S. and published as U.S. Pub. No. 2014/0023674.Related Scientific References Licensing OpportunitiesWe are currently seeking licensing opportunities in all fields for the development of this technology. Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

Country/Region

USA